Antineoplastic Agents

Bendamostine hydrochloride was first developed by ozegowski and his colleagues in the microbial experimental Association in Jena, Germany in the early 1860s. The initial purpose was to connect an alkylated nitrogen mustard (a non effective alkylating agent) with a purine and an amino acid. Compared with nitrogen mustard phenylbutyrate, the main advantage of the newly synthesized compound is its water solubility. It was widely used, but until the end of the cold war, the drug has been carried out in Europe for many single drugs or other drugs for the treatment of various hematological malignancies or non Hodgkin's lymphoma, multiple myeloma, CLL and breast cancer. The clinical effect is very significant, significantly reducing the rate of recurrence and mortality, and has little side effects. Good security. So far, bendamostine hydrochloride single drug or combined treatment has been designated as the first-line or second-line treatment option for a variety of hematological malignancies by European and American clinical guidelines.

Tamoxifen citrate is a kind of estrogen competitive antagonist, which is a non steroidal anti estrogen drug. It can compete with estrogen in vivo and combine with estrogen receptor of breast cancer cells, so as to inhibit the effect of estrogen on cancer cells, hinder the growth and development of tumor cells, and play an anti-cancer effect. It is commonly used in the treatment of various types of breast cancer. It is especially suitable for women with postmenopausal breast cancer who have estrogen receptor and progesterone receptor positive and low level of prostate specific antigen.

Letrozole is a new generation of highly selective aromatase inhibitor, which is a synthetic benzyltriazole derivative. By inhibiting aromatase, letrozole can reduce the level of estrogen, so as to eliminate the stimulating effect of estrogen on tumor growth. The in vivo activity is 150-250 times stronger than that of the first generation aromatase inhibitor amlumide. Because of its high selectivity, it does not affect the function of glucocorticoid, mineralocorticoid and thyroid. High dose use has no inhibitory effect on the secretion of adrenal corticosteroids, so it has a high therapeutic index. Preclinical studies have shown that letrozole has no potential toxicity, mutagenic and carcinogenic effects on various systems and target organs of the body, and has less toxic and side effects, good tolerance. Compared with other aromatase inhibitors and anti estrogen drugs, letrozole has stronger anti-tumor effect. It is suitable for the treatment of patients with advanced breast cancer who are not effective in the treatment of estrogen and early treatment of breast cancer.

This product can be used as medicine raw material and anti-tumor drug.

Oxaliplatin, which belongs to platinum derivatives and is clinically used to treat patients with colorectal cancer metastases after failure of fluorouracil treatment, either alone or in combination with fluorouracil, is the third-generation novel platinum based antitumor compound after cisplatin, carboplatin and the only complex platinum based drug with significant activity against colorectal cancer to date. The principle of action is to act on DNA by producing alkylated conjugates, forming intra - and interstrand crosslinks that inhibit DNA synthesis and replication. It also inhibited proliferation in ovarian cancer and melanoma cell lines.